16: The Smartest Doctor in the Room with Dean Mitchell, MD - Episode 1616: The Smartest Doctor in the Room with Dean Mitchell, MD - Episode 16
UK Health Radio Podcast
Dr. Dean Mitchell speaks with Dr. Lawrence Lustig about a newly approved gene therapy for a rare genetic form of childhood deafness and how it compares with cochlear implants. They also discuss early diagnosis, future research into more common hearing loss, and practical ways to protect hearing over time.
33:08•29 Sept 2026
Gene Therapy, Hearing Restored: Dr Lawrence Lustig Talks Future of Deafness Treatment
Episode Overview
- Otofarmaní is an FDA-approved, one-time inner ear gene therapy for a rare otoferlin-related childhood deafness, with most early patients showing significant hearing improvement.
- Gene therapy can provide more natural hearing than cochlear implants, often with better music appreciation and without permanent hardware in the skull.
- Early diagnosis of hearing loss in infants is crucial; acoustic brainstem response (ABR) testing is preferred over otoacoustic emissions for detecting otoferlin-related auditory neuropathy.
- There is currently no strong evidence of serious complications directly linked to this gene therapy across multiple international centres using similar approaches.
- Protecting ears from loud noise with proper earplugs is the key modifiable way to reduce hearing loss risk over a lifetime.
“With this one and done gene therapy, we can give kids natural hearing.”
What drives someone to seek a life without barriers like silence? This conversation between Dr. Dean Mitchell and otologist–neurotologist Dr. Lawrence Lustig centres on a groundbreaking gene therapy that may let some children hear for the first time. Dr. Lustig explains Otofarmaní, “a one and done injection” into the inner ear that targets a rare genetic cause of childhood deafness involving the otoferlin gene.
He breaks down the science in plain language: how sound turns into electrical signals, why a single faulty gene can act like a flipped switch, and how researchers worked out a way to split a large gene into two viral vectors so it could fit into the delivery system. It sounds like science fiction, but as he notes, “three quarters of them had dramatic improvement in hearing” among the first 12 treated children.
You’ll hear how this treatment compares with cochlear implants, including real-world pros and cons. Cochlear implants can be life-changing, but as Dr. Lustig points out, “you’ve got to now walk around for the remainder of your life with hardware in your skull,” while gene therapy aims to restore more natural hearing, sometimes with just hearing aids for support.
The episode also looks at why early detection of hearing loss in babies is critical, the limits of current tests, and why some forms of deafness are easier to treat than others.
There’s a candid discussion about future hopes for more common genetic and age-related hearing loss, plus a very practical tip: protect your ears from loud noise, because “noise adds up over time.” If you or someone you care about lives with hearing loss—or you’re simply curious about where medical science is headed—this conversation might leave you asking: what could this kind of gene therapy mean for millions more in the years ahead?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.